Artal Group’s Esperion Therapeutics ESPR Stock Holding History

Artal Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-250,000	Closed	-$9.29M	–	138
2020 Q3	$9.29M	Buy	+250,000	New	+$9.9M	0.23%	79

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group's ESPR Position: Q4 2020 in Review

Artal Group sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 250,000 shares — an estimated $9.29M sold.

Artal Group first reported a position in ESPR in Q3 2020 and held it in 1 quarter. The position peaked at $9.29M in Q3 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

Artal Group reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
Artal Group sold 250,000 Esperion Therapeutics shares in Q4 2020, an estimated $9.29M.
Artal Group first reported a position in Esperion Therapeutics in Q3 2020 and held it in 1 quarter.
Artal Group's Esperion Therapeutics position peaked at $9.29M in Q3 2020.
157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.